...
首页> 外文期刊>Frontiers in Public Health >Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation
【24h】

Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation

机译:流行病学和人乳头瘤病毒和相关疾病的负担,分子发病机制和疫苗评价

获取原文

摘要

Diagnosed in more than 90% of cervical cancers, the fourth deadliest cancer in women, human papillomavirus (HPV) is currently the most common pathogen responsible for female cancers. Moreover, HPV infection is associated with many other diseases, including cutaneous and anogenital warts, and genital and upper aerodigestive tract cancers. The incidence and prevalence of these pathologies vary considerably depending on factors including HPV genotype, regional conditions, the study population, and the anatomical site sampled. Recently, features of the cervicovaginal microbiota are found to be associated with the incidence of HPV-related diseases, presenting a novel approach to identify high-risk women through both blood and cervical samples. Overall, the HPV repartition data show that HPV infection and related diseases are more prevalent in developing countries. Moreover, the available (2-, 4-, and 9-valent) vaccines based on virus-like particles, despite their proven effectiveness and safety, present some limitations in terms of system development cost, transport cold chain, and oncogenic HPV variants. In addition, vaccination programs face some challenges, leading to a considerable burden of HPV infection and related diseases. Therefore, even though the new (9-valent) vaccine seems promising, next-generation vaccines as well as awareness programs associated with HPV vaccination and budget reinforcements for immunization are needed.
机译:诊断出超过90%的宫颈癌,第四次致命的女性致命癌症,人乳头瘤病毒(HPV)是目前最常见的病原体负责雌性癌症。此外,HPV感染与许多其他疾病有关,包括皮肤和源性疣,以及生殖器和上部空气衰弱癌症。这些病理的发病率和患病率随着包括HPV基因型,区域条件,研究人群和解剖部位的因素而变化很大。最近,发现宫颈病毒微生物群的特征与HPV相关疾病的发病率有关,呈现一种通过血液和宫颈样品鉴定高危女性的新方法。总体而言,HPV重置数据显示,HPV感染和相关疾病在发展中国家更为普遍。此外,尽管其经过验证的有效性和安全性,但在系统开发成本,运输冷链和致癌型HPV变体方面存在一些局限性,仍基于病毒样粒子的可用(2-4-和9价)疫苗。此外,疫苗接种计划面临着一些挑战,导致HPV感染和相关疾病的相当负担。因此,即使新的(9价)疫苗似乎有望,需要下一代疫苗以及与HPV疫苗接种相关的意识计划和用于免疫的预算增强。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号